MedPath

Clinical effectiveness of Unani drugs in comparison to conventional drug in the treatment of dyslipidaemia (abnormal amount of fat in the blood)

Phase 2
Conditions
Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified
Registration Number
CTRI/2019/05/019066
Lead Sponsor
Central Research Institute of Unani Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Participants of any sex aged 30-60 years.

Participants with having following lipid or lipoprotein abnormality

in blood-

- Serum Cholesterol equal to or more than 200mg/dl.

- HDL-C less than 40 mg/dl

- LDL Cholesterol equal to or more than 130 mg/dl.

- Serum Triglycerides level equal to or more than

150mg/dl.

Both obese and non-obese.

Exclusion Criteria

Participants aged less than 30 and more than 60 years.

Participants having a co-morbid condition like IHD, HT, Diabetes, etc.

Participants having a major systemic disorder which interferes in the

present study.

Pregnant or Lactating Women.

Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction

Known cases of Immunocompromised states (HIV/ AIDS,

etc.)/Malignancies

Participant not willing to attend treatment schedule regularly

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Biochemical assessment of the change in Lipid and Lipoprotein levelTimepoint: At baseline, 2nd, 3rd and 4th followups
Secondary Outcome Measures
NameTimeMethod
Hemogram LFT, RFT, FPG, ECG and Urine R/M examinationTimepoint: At baseline, 3rd followup and after treatment, except ECG that will be at baseline and after treatment
© Copyright 2025. All Rights Reserved by MedPath